PIONEER big data platform for prostate cancer: lessons for advancing future real-world evidence research
Research output: Contribution to journal › Research article › Contributed › peer-review
Contributors
- Department of Urology
- King's College London (KCL)
- Erasmus University Rotterdam
- Collaborate Project Management
- Lund University
- European Institute for Systems Biology and Medicine (EISBM)
- University of Aberdeen
- Koninklijke Philips N.V.
- Rotterdam University of Applied Sciences
- Bayer AB
- European Association of Urology (EAU)
- Hospital Clinico Universitario San Carlos
- Vita-Salute San Raffaele University
- University of Florence
- Hippokration General Hospital
- ARTTIC Innovation GmbH
- Bayer AG
- Pinsent Masons LLP
- Astellas Pharma Inc.
- The Hyve
- European Alliance for Personalized Medicine
- IQVIA Inc.
- Ludwig Maximilian University of Munich
- AstraZeneca
- Ecancer
- Johnson & Johnson
- SAS Belgium
- Sanofi S.A.
- The Swedish Institute for Health Economics (IHE)
- Radboud University Nijmegen
- University of Gothenburg
- Department of Urology
Abstract
Prostate Cancer Diagnosis and Treatment Enhancement through the Power of Big Data in Europe (PIONEER) is a European network of excellence for big data in prostate cancer. PIONEER brings together 34 private and public stakeholders from 9 countries in one multidisciplinary research consortium with the aim of positively transforming the field of prostate cancer clinical care by answering pressing questions related to prostate cancer screening, diagnosis and treatment. PIONEER has developed a unique state-of-the-art big data analytic platform by integrating existing data sources from patients with prostate cancer. PIONEER leveraged this platform to address prioritized research questions, filling knowledge gaps in the characterization, management and core outcomes of prostate cancer across the different disease stages. The network has benefited from sustained patient and stakeholder involvement and engagement, but many challenges remain when using real-world data for big data projects. To continue to advance prostate cancer care, data need to be available, suitable methodologies should be selected and mechanisms for knowledge sharing must be in place. Now acting as the prostate cancer arm of the European Association of Urology’s new endeavour, UroEvidenceHub, PIONEER maintains its goal of maximizing the potential of big data to improve prostate cancer care.
Details
Original language | English |
---|---|
Article number | e058267 |
Pages (from-to) | 116-124 |
Number of pages | 9 |
Journal | Nature Reviews Urology |
Volume | 22 |
Issue number | 2 |
Publication status | Published - Feb 2025 |
Peer-reviewed | Yes |